Novartis's Sandoz to Invest in Antibiotic Manufacturing in Europe
By Cecilia Butini
Novartis AG said Tuesday that its generics division Sandoz is
investing in new antibiotics-manufacturing technology in Europe
over the next three to five years, expanding two sites and
foreseeing the closure of a third.
The investment, which amounts to a total of 150 million euros
($182.3 million), is for the company's facilities in Kundl,
Austria, and Palafolls, Spain, Novartis said.
As part of the plan, Sandoz is set to phase out its current
production of active pharmaceutical ingredients at its Les
Franqueses site in Spain, which it plans to close by 2024, Novartis
said. Production of sterile active pharmaceutical ingredients is
set to be transferred from Kundl to Palafolls in 2025, according to
The company added that it would offer full support to employees
who might be affected by the changes.
Write to Cecilia Butini at email@example.com
(END) Dow Jones Newswires
May 18, 2021 05:14 ET (09:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.